| [1] |
. Exp Ther Med，2015，9（2）：603-611.
|
| [2] |
Hou K，Li YM. Developments on novel molecular targets participating in myocardial ischemia reperfusion injury［J］. Med Res Educ（医学研究与教育），2020，37（3）：1-9.
|
| [3] |
Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective［J］. Nat Rev Cardiol，2020，17（12）：773-789.
|
| [4] |
Hausenloy DJ，Botker HE，Engstrom T，et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction：trials and tribulations［J］.Eur Heart J，2017，38（13）：935-941.
|
| [5] |
Heusch G，Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion：a continual challenge［J］.Eur Heart J，2017，38（11）：774-784.
|
| [6] |
Hausenloy DJ，Garcia-Dorado D，B?tker HE，et al. Novel targets and future strategies for acute cardioprotection：position paper of the european society of cardiology working group on cellular biology of the heart［J］.Cardiovasc Res，2017，113（6）：564-585.
|
| [7] |
Inserte J，Hernando V，Vilardosa ú，et al. Activation of cGMP/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling［J］.J Am Heart Assoc，2013，2（1）：e005975.
|
| [8] |
Szabó MR，Pipicz M，Csont T，et al. Modulatory effect of myokines on reactive oxygen species in ischemia/reperfusion［J］.Int J Mol Sci，2020，21（24）：9382.
|
| [9] |
Kleinbongard P，Amanakis G，Skyschally A，et al. Reflection of cardioprotection by remote ischemic perconditioning in attenuated ST-segment elevation during ongoing coronary occlusion in pigs：evidence for cardioprotection from ischemic injury［J］ Circ Res，2018，122（8）：1102-1108.
|
| [10] |
Figueras J，Otaegui I，Marti G，et al. Area at risk and collateral circulation in a first acute myocardial infarction with occluded culprit artery. STEMI vs non-STEMI patients［J］. Int J Cardiol，2018，259：14-19.
|
| [11] |
Ibanez B，James S，Agewall S，et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation：the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology （ESC）［J］.Eur Heart J，2018，39（2）：119-177.
|
| [12] |
Abrial M，da Silva CC，Pillot B，et al. Cardiac fibroblasts protect cardiomyocytes against lethal ischemia-reperfusion injury［J］.J Mol Cell Cardiol，2014，68：56-65.
|
| [13] |
Hausenloy DJ，Chilian W，Crea F，et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury：a target for cardioprotection［J］.Cardiovasc Res，2019，115（7）：1143-1155.
|
| [14] |
Schanze N，Bode C，Duerschmied D. Platelet contributions to myocardial ischemia/reperfusion injury［J］.Front Immunol，2019，10：1260.
|
| [15] |
Fernández-Jiménez R，Barreiro-Pérez M，Martin-García A，et al. Dynamic edematous response of the human heart to myocardial infarction：implications for assessing myocardial area at risk and salvage［J］.Circulation，2017，136（14）：1288-1300.
|
| [16] |
Schwiebert C，Huhn R，Heinen A，et al. Postconditioning by xenon and hypothermia in the rat heart in vivo［J］.Eur J Anaesthesiol，2010，27（8）：734-739.
|
| [17] |
Alburquerque-Béjar JJ，Barba I，Inserte J，et al. Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs［J］.Cardiovasc Res，2015，107（2）：246-254.
|
| [18] |
Sun JH，Aponte AM，Menazza S，et al. Additive cardioprotection by pharmacological postconditioning with hydrogen sulfide and nitric oxide donors in mouse heart：S-sulfhydration vs. S-nitrosylation［J］.Cardiovasc Res，2016，110（1）：96-106.
|
| [19] |
Alexopoulos P，Panoutsopoulou K，Vogiatzis G，et al. Combined treatment with exenatide and cyclosporine A or parstatin 1-26 results in enhanced reduction of infarct size in a rabbit model［J］.J Cardiovasc Pharmacol，2017，70（1）：34-41.
|
| [20] |
Koshinuma S，Miyamae M，Kaneda K，et al. Combination of necroptosis and apoptosis inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury［J］.J Anesth，2014，28（2）：235-241.
|
| [21] |
Audia JP，Yang XM，Crockett ES，et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y 12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function［J］.Basic Res Cardiol，2018，113（5）：32.
|
| [22] |
Aryal B，Price NL，Suarez Y，et al. ANGPTL4 in metabolic and cardiovascular disease［J］. Trends Mol Med，2019，25（8）：723-734.
|
| [23] |
Lux A，Pokreisz P，Swinnen M，et al. Concomitant phosphodiesterase 5 inhibition enhances myocardial protection by inhaled nitric oxide in ischemia-reperfusion injury［J］.J Pharmacol Exp Ther，2016，356（2）：284-292.
|
| [24] |
Yang XM，Cui L，White J，et al. Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion［J］.Basic Res Cardiol，2015，110（2）：3.
|
| [25] |
Xin P，Zhu W，Li J，et al. Combined local ischemic postconditioning and remote perconditioning recapitulate cardioprotective effects of local ischemic preconditioning［J］.Am J Physiol Heart Circ Physiol，2010，298（6）：H1819-H1831.
|
| [26] |
Huang MH，Wu YW，Nguyen V，et al. Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion［J］.Cardiovasc Drugs Ther，2011，25（3）：223-232.
|
| [27] |
Fan Y，Yang SS，Zhang XK，et al. Comparison of cardioprotective efficacy resulting from a combination of atorvastatin and ischaemic post-conditioning in diabetic and non-diabetic rats［J］. Clin Exp Pharmacol Physiol，2012，39（11）：938-943.
|
| [28] |
Tratsiakovich Y，Gonon AT，Kiss A，et al. Myocardial protection by co-administration of L-arginine and tetrahydrobiopterin during ischemia and reperfusion［J］.Int J Cardiol，2013，169（1）：83-88.
|
| [29] |
Wang Q，Liu GP，Xue FS，et al. Combined vagal stimulation and limb remote ischemic perconditioning enhances cardioprotection via an anti-inflammatory pathway［J］.Inflammation，2015，38（5）：1748-1760.
|
| [30] |
Eitel I，Stiermaier T，Rommel KP，et al. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction：the randomized LIPSIA CONDITIONING trial［J］.Eur Heart J，2015，36（44）：3049-3057.
|
| [31] |
Pasupathy S，Tavella R，Grover S，et al. Early use of N-acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction reduces myocardial infarct size （the NACIAM trial［N-acetylcysteine in acute myocardial infarction］）［J］.Circulation，2017，136（10）：894-903.
|
| [32] |
Rout A，Sukhi A，Chaudhary R，et al. Investigational drugs in phase II clinical trials for acute coronary syndromes［J］.Expert Opin Investig Drugs，2020，29（1）：33-47.
|
| [33] |
Ziegler M，Haigh K，Nguyen T，et al. The pulmonary microvasculature entraps induced vascular progenitor cells （iVPCs） systemically delivered after cardiac ischemia-reperfusion injury：indication for preservation of heart function via paracrine effects beyond engraftment［J］. Microcirculation，2019，26（2）：e12493.
|
| [34] |
Audia JP，Yang XM，Crockett ES，et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y 12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function［J］.Basic Res Cardiol，2018，113（5）：32.
|
| [35] |
Rossello X，Yellon DM. The RISK pathway and beyond［J］. Basic Res Cardiol，2017，113（1）：1-5.
|
| [36] |
Yang XL，Yue RC，Zhang J，et al. Gastrin protects against myocardial ischemia/reperfusion injury via activation of RISK （reperfusion injury salvage kinase） and SAFE （survivor activating factor enhancement） pathways［J］.J Am Heart Assoc，2018，7（14）：e005171.
|
| [37] |
Olshan DS，Rader DJ. Angiopoietin-like protein 4：a therapeutic target for triglycerides and coronary disease［J］？J Clin Lipidol，2018，12（3）：583-587.
|
| [38] |
Gibson CM，Giugliano RP，Kloner RA，et al. EMBRACE STEMI study：a Phase 2a trial to evaluate the safety，tolerability，and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention［J］.Eur Heart J，2016，37（16）：1296-1303.
|
百度学术
下载:
